98786-86-8

Upstream product

• 15862-34-7 5-bromo-3-nitro-2-pyridone 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 

Downstream Products

• 108870-77-5 6-bromo-2-phenyloxazolo[5,4-b]pyridine 
• 102170-55-8 N-(5-bromo-2-hydroxy-[3]pyridyl)-acetamide 
• 869645-73-8 N-(5-bromo-2-hydroxypyridin-3-yl)-4-(trifluoromethyl)benzamide 
• 1616402-98-2 C₁₂H₁₀BrClN₂O 
• 1616402-06-2 3-amino-1-(4-chlorobenzyl)-5-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)pyridin-2(1H)-one 
• 1616402-99-3 C₁₈H₂₂BClN₂O₃ 
• 1616401-81-0 3-amino-5-(3,5-dimethylisoxazol-4-yl)-1-(4-fluorobenzyl)pyridin-2(1H)-one 
• 1616402-87-9 C₁₂H₁₀BrFN₂O 
• 869645-75-0 (S)-2-[5-Naphthalen-1-yl-2-oxo-3-(4-trifluoromethylbenzoylamino)-2H-pyridin-1-yl]-3-phenylpropionic acid methyl ester 
• 869645-74-9 (S)-2-[5-bromo-2-oxo-3-(4-trifluoromethylbenzoylamino)-2H-pyridin-1-yl]-3-phenylpropionic acid methyl ester 
• 33630-99-8 2-hydroxy-3-aminopyridine 

Relevant academic research and scientific papers

Synthesis and applications of 3-amino-2-hydroxypyridine

The invention discloses synthesis and applications of 3-amino-2-hydroxypyridine. The synthesis steps comprise: (1) dissolving 2-hydroxy-3-nitro-5-bromopyridine in a solvent, stirring, adding the mixture of iron powder and hydrochloric acid, carrying out a reaction for 0.5-1 h, and carrying out post-treatment to obtain 2-hydroxy-3-amino-5-bromopyridine; and (2) dissolving the 2-hydroxy-3-amino-5-bromopyridine obtained in the step (1) in an alkaline solution, adding strontium carbonate, introducing hydrogen into a reaction bottle, carrying out a reaction for a certain time, and carrying out conventional treatment to obtain 3-amino-2-hydroxypyridine. According to the present invention, the production cost is substantially reduced, and the obtained 3-amino-2-hydroxypyridine has the high purityand can be directly used in the next step.

Pyridone compounds as inhibitors of bacterial type III protien secreation systems

In accordance with the present invention, compounds that inhibit Type III protein section have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of Type III protein section and/or in the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections, are provided. In another aspect of the invention, methods are provided for the inhibition of Type III protein secretion and/or the treatment and prevention of bacterial infections, particularly Gram-negative bacterial infections using the compounds of the invention.

Pharmaceutical compositions for CNS and other disorders

The present invention relates to a method of treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal a CNS-penetrant α7 nicotinic receptor agonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and a CNS-penetrant α7 nicotinic receptor agonist.

Condensation of 2,3-pyridinediamines with acetonylacetone

The reaction of 2,3-pyridinediamine 1a and its 5-bromo analogue 1b, independently, with acetonylacetone leads to the formation of 1:1 condensation products irrespective of the molar ratios employed.'The condensation products have been assigned 2-amino 2a and 5-bromo-2-amino-3 (2',5'-dimethylpyrrolyl)pyridine 2b structures. Authentic chemical evidence is given in support of the claim for these structures ruling out the equally probable alternative structure 3 for these compounds. Attempted studies on the reactivity of the latter compounds towards electrophilic reagents such as acetic arthydride, benzoyl chloride, and arylsulphonyl chlorides have been described.